We are very excited to announce that we have closed the two newest funds of the TCG fund family – The Column Group V (“TCG V”), a $615 million fund focused on early-stage investments, and The Column Group Opportunity III (“TCG Opportunity III”), also $615 million but focused on later stage investments in our companies. …
The Column Group Raises $1.23 Billion in Two New Funds Read More »
The Column Group announces the hiring of Dr. Hui Tian. Previously, Dr. Tian was a founding member of NGM Biopharmaceuticals and most recently served as Senior Vice President of Research. In this role, he was responsible for discovery research across multiple therapeutic areas including metabolic diseases, retinal diseases and cancer. In a span of 14 …
Dr. Hui Tian joins The Column Group as Venture Partner Read More »
The Column Group announces the promotion of Dr. Sarah Hymowitz from Venture Partner to Partner. Dr. Hymowitz has been with TCG since 2021.
The Column Group announces the promotion of Dr. Millie Ray from Principal to Partner. Dr. Ray has been with TCG since 2017.
The Column Group announces the hiring of Mr. Jeff Goater. Previously, Mr. Goater served as Chief Executive Officer of Surface Oncology. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team.
The Column Group announces the hiring of Dr. Sarah Gillmor Hymowitz. Previously, Dr. Hymowitz spent 22 years at Genentech rising to Vice President of Protein Sciences. In this role, she oversaw the large molecule drug discovery portfolio and mentored project teams on the identification and optimization of more than 35 clinical candidates.
Widely considered to be the father of the biotechnology industry, Robert Swanson changed the world when he founded Genentech with Herbert Boyer in 1976. TCG’s new fellowship program pays homage to Robert Swanson’s legacy, empowering the next generation of young visionaries on their quest to better the world through science and medicine. The Column Group …
TCG Launches the Swanson Fellowship Program and Dr. Tobias Schmid joins as first Fellow Read More »
TCG’s iPartners represents a new ideation advisory group comprised of leading academic investigators and biotech entrepreneurs. Working closely with TCG’s Swanson Fellows and our core investment team, this group is dedicated to crafting innovative new drug discovery company concepts, drawing on their deep scientific expertise, academic and industry networks, and entrepreneurial intuition. The iPartners consist …
The Column Group announced the recruitment of Dr. Eric Olson to the firm’s renowned group of Science Partners. Dr. Olson is the founding Chair of the Department of Molecular Biology at The University of Texas Southwestern Medical Center. He also founded the Center for Regenerative Science and Medicine at UT Southwestern, which is advancing new …
Dr. Eric Olson joins The Column Group as Science Partner Read More »
The Column Group announces the hiring of Dr. John Josey. Previously, Dr. Josey served as the President, Chief Executive Officer and a member of the Board of Directors of Peloton Therapeutics, from 2013 until its acquisition by Merck in 2019. He joined Peloton in 2011 as the first employee in the role of President and …
Dr. John Josey joins The Column Group as Venture Partner Read More »
